(Sharecast News) - Fusion Antibodies said on Tuesday that full-year revenue rose and margins had improved sharply, as the pre-clinical antibody specialist made progress with platform development, grant-funded programmes and larger pharmaceutical customers.
The AIM-listed company said unaudited revenue for the year ended 31 March rose about 9% to £2.13m, from...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE